# Circle Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/circle-pharma

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.circlepharma.com
- Total disclosed funding: $111M
- Latest round: Series D (Jun 28, 2024)
- Investors on record: 13

## About

Circle Pharma, Inc. specializes in developing innovative macrocycle therapeutics aimed at treating various advanced solid tumors. The company focuses on utilizing its proprietary MXMO™ platform to deliver effective cancer therapies.Circle Pharma, Inc., established in 2012 and headquartered in San Francisco, US, focuses on creating cell-permeable macrocycle therapeutics. The company was founded by Matt Jacobson and has raised a total of USD 9.00 mn, primarily through its most recent funding round, Series D, completed in August 2024. The company has engaged in a total of 8 funding deals, demonstrating its commitment to advancing cancer treatment options. David Earp currently serves as CEO.Circle Pharma, Inc. specializes in the development of cell-permeable macrocycle therapeutics, focusing on its proprietary MXMO™ platform. Its leading product, CID-078, is a first-in-class oral macrocycle cyclin A/B RxL inhibitor undergoing Phase 1 clinical trials for advanced solid tumors, including small cell lung cancer, triple-negative breast cancer, and estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. CID-078 selectively targets oncogenic alterations that disrupt cell cycle regulation, aiming to provide improved treatment options in the US oncology market.Circle Pharma's revenue model revolves around partnerships and clinical trials as it advances its investigational therapies. Collaborations with research institutions and pharmaceutical partners support the development and commercialization of its macrocycle therapeutics. Revenue may arise from milestone payments associated with clinical trial advancements, regulatory approvals, and product launches. Additionally, licensing agreements may yield upfront payments and royalties based on product sales. CID-078 serves as a key component in this revenue structure, addressing crucial challenges in cancer treatment.Circle Pharma, Inc. plans to utilize the recent USD 9.00 mn in venture funding raised in August 2024 to further its development of innovative cancer therapies. The company aims to advance CID-078 through clinical trials and is exploring the potential introduction of additional products based on its MXMO™ platform. Future expansion is targeted towards new geographic markets, particularly within the US, where there is an urgent need for effective cancer therapeutics. As the company progresses with its pipeline, it is focused on meeting critical demands in oncology care.

## Funding rounds

- Series D, Jun 28, 2024, $54M — The Column Group, Nextech, Euclidean Capital
- Series C, Jun 15, 2021, $36M — The Column Group, Nextech, Euclidean Capital, Pandect Bioventures, Hartford HealthCare Corporation
- Series B, Mar 16, 2020, $15M — The Column Group, Nextech, Shanghai ChemPartner Co., Ltd., LifeForce Capital, Berkeley Catalyst Fund
- Series A, Apr 18, 2017, $2.7M — Whitesun Equity Partners, WI Harper Group, Element Partners, Mission Bay Capital, Pfizer Inc., Shanghai ChemPartner Co., Ltd., LifeForce Capital
- Series A, Sep 6, 2016, $3.8M — Mission Bay Capital, Pfizer Inc., Shanghai ChemPartner Co., Ltd.
- Seed, Sep 22, 2014 — Mission Bay Capital, Pfizer Inc.

## Investors

- Mission Bay Capital (https://capitalatlas.ai/funds/mission-bay-capital) — Seed, Series A
- Pfizer Inc. — Seed, Series A
- Shanghai ChemPartner Co., Ltd. — Series A, Series B
- Whitesun Equity Partners (https://capitalatlas.ai/funds/whitesun-equity-partners) — Series A
- WI Harper Group (https://capitalatlas.ai/funds/wi-harper-group) — Series A
- Element Partners (https://capitalatlas.ai/funds/element-partners) — Series A
- LifeForce Capital (https://capitalatlas.ai/funds/lifeforce-capital) — Series A, Series B
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series B, Series C, Series D
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B, Series C, Series D
- Berkeley Catalyst Fund (https://capitalatlas.ai/funds/berkeley-catalyst-fund) — Series B
- Euclidean Capital — Series C, Series D
- Pandect Bioventures (https://capitalatlas.ai/funds/pandect-bioventures) — Series C
- Hartford HealthCare Corporation — Series C